Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

NCT05896748 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus Type 1 (HIV-1)

Interventions

DRUG: Cabotegravir - Injectable Suspension (CAB LA)
DRUG: Rilpivirine - Injectable Suspension (RPV LA)

Sponsor

ViiV Healthcare

Collaborators

[object Object]
[object Object]